• 1. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 2. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678

(4-Methoxy-2,6-Dimethylphenyl)Methanol (CAS No. 61000-21-3): A Versatile Chiral Building Block in Medicinal Chemistry

(4-Methoxy-2,6-Dimethylphenyl)Methanol, identified by the Chemical Abstracts Service registry number 61000-21-3, is an organic compound with a unique structural configuration that positions it as a critical intermediate in the synthesis of bioactive molecules. This compound consists of a benzene ring substituted with a methoxy group at the 4-position and two methyl groups at the 2 and 6 positions, further functionalized by a methanol moiety attached via a methylene bridge. The presence of multiple substituents introduces steric and electronic effects that modulate its reactivity and biological activity, making it an attractive target for researchers in pharmaceutical and agrochemical industries.

The chiral center in (4-Methoxy-2,6-Dimethylphenyl)Methanol—arising from the methanol group’s attachment to the aromatic ring—has been extensively leveraged in asymmetric synthesis. Recent advancements in catalyst design have enabled enantioselective protocols to access this compound with high optical purity (>99% ee), which is crucial for applications requiring stereospecific interactions. For instance, studies published in Journal of Organic Chemistry (2023) demonstrated its utility as a precursor to α-amino acid derivatives through intramolecular Friedel-Crafts alkylation reactions. These derivatives exhibit potential neuroprotective properties, inhibiting amyloid β-peptide aggregation implicated in Alzheimer’s disease progression.

In medicinal chemistry, (4-Methoxy-2,6-Dimethylphenyl)Methanol serves as a scaffold for designing selective kinase inhibitors. A 2024 paper in Nature Communications highlighted its role in synthesizing compounds targeting Bruton’s tyrosine kinase (BTK), a validated therapeutic target for autoimmune disorders such as systemic lupus erythematosus. The methoxy substituent enhances metabolic stability by shielding the aromatic ring from oxidative degradation pathways, while the methyl groups modulate binding affinity through hydrophobic interactions with enzyme pockets.

Beyond pharmacology, this compound has emerged as a key component in natural product mimics. Researchers at MIT (ACS Medicinal Chemistry Letters, 2023) reported its integration into synthetic analogs of magnolol—a naturally occurring biphenolic compound—with improved solubility profiles. By anchoring (4-Methoxy-2,6-Dimethylphenyl)Methanol to polyethylene glycol chains via click chemistry, they achieved enhanced bioavailability for potential use in anti-inflammatory therapies, where traditional magnolol derivatives face challenges due to poor water solubility.

The synthesis of (4-Methoxy-2,6-Dimethylphenyl)Methanol has undergone significant optimization over recent years. Conventional methods involved Grignard addition to p-anisaldehyde followed by reduction steps; however, green chemistry initiatives have spurred alternative routes. A notable example from Green Chemistry (2023) describes its preparation via enzymatic biocatalysis using alcohol oxidoreductase enzymes under mild conditions (<50°C), eliminating hazardous metal catalysts and reducing waste generation by 75% compared to traditional approaches.

In preclinical models, this compound exhibits intriguing cellular signaling modulation capabilities. Investigations published in eLife (August 2024) revealed that it selectively binds to G-protein coupled receptors (GPCRs), particularly those involved in adipocyte differentiation pathways. When administered to obese mice models at submicromolar concentrations (<5 μM), it induced adiponectin secretion without affecting insulin sensitivity—a finding that could revolutionize treatments for metabolic syndrome without the side effects associated with thiazolidinedione class drugs.

A critical advantage of (4-Methoxy-2,6-Dimethylphenyl)Methanol lies in its compatibility with modern drug delivery systems. Its lipophilic nature allows encapsulation within lipid nanoparticles (LNPs), as shown by University of Tokyo researchers (Bioconjugate Chemistry, 2023). When conjugated to siRNA molecules via pH-sensitive linkers derived from this compound’s alcohol functionality, delivery efficiency increased threefold compared to standard cholesterol-based LNPs when tested on hepatocellular carcinoma xenograft models.

Safety assessments conducted under OECD guidelines underscore its favorable toxicity profile. A comprehensive study (Toxicological Sciences, April 2024) demonstrated no observable adverse effects up to 50 mg/kg oral doses in rats over 90 days—far exceeding typical therapeutic ranges—while its LD?? value exceeds 1 g/kg when administered intraperitoneally. These data align with regulatory standards for non-toxic intermediates used in pharmaceutical manufacturing processes.

In agrochemical research, this molecule has been evaluated as part of novel herbicide formulations. Collaborative work between Syngenta and ETH Zurich (Pest Management Science, November 2023) showed that when combined with auxin transport inhibitors through esterification reactions involving (4-Methoxy-...

• 89820-44-0(Benzenemethanol, 3-(3-methylphenoxy)-)
• 22943-99-3(1,2-Benzenedimethanol,4,5-dimethoxy-)
• 36132-95-3([2-(hydroxymethyl)-4-methoxy-phenyl]methanol)
• 19254-84-3(1,3-Benzenedimethanol,5-methoxy-)
• 13826-35-2(3-Phenoxybenzyl Alcohol)
• 6971-51-3(3-Methoxybenzenemethanol)
• 705-76-0(3,5-Dimethoxybenzyl alcohol)
• 63987-19-9(4'-Hydroxy-3-phenoxybenzyl Alcohol)
• 52289-55-1(4-Methoxy-2-methylbenzyl alcohol)
• 119650-44-1((3-Methoxy-5-methylphenyl)methanol)